Dermata Therapeutics regains Nasdaq compliance with publicly held shares rule

Dermata Therapeutics, Inc.

Received Nasdaq deficiency notice on May 20, 2024 for failing Rule 5550(a)(4) requiring at least 500,000 publicly held shares.
Provided additional information and as of May 24, 2024, the Company has regained compliance and the matter is closed.
No further action required; common stock (DRMA) and warrants (DRMAW) remain listed on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.